RankingsPricing
  1. US-listed companies
  2. ALNYLAM PHARMACEUTICALS, INC.
  3. Financials
  4. Total liabilities

ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap
$56.6B
P/E ratio
SummaryFinancials
Period EndTotal liabilities (Million USD)YoY (%)
Dec 31, 20244,173+3.02%
Dec 31, 20234,051+9.34%
Dec 31, 20223,705+21.26%
Dec 31, 20213,055+27.78%
Dec 31, 20202,391+149.97%
Dec 31, 2019956+250.55%
Dec 31, 2018273+19.51%
Dec 31, 2017228-33.36%
Dec 31, 2016343+181.28%
Dec 31, 2015122-15.02%
Dec 31, 2014143-4.56%
Dec 31, 2013150-2.14%
Dec 31, 2012153-6.38%
Dec 31, 2011164-30.26%
Dec 31, 2010235

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)